MAM
PTCT icon

Marquette Asset Management’s PTC Therapeutics PTCT Stock Holding History

Marquette Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12K Hold
26
– – ﹤0.01% 593
2026
Q1 		$1.77K Buy
26
+19
+271% +$1.34K ﹤0.01% 571
2025
Q4 		$532 Buy
+7
New +$509 ﹤0.01% 645

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Marquette Asset Management's PTCT Position: Q2 2026 in Review

Marquette Asset Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 26 shares worth $2.12K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Marquette Asset Management first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Marquette Asset Management held 26 shares of PTC Therapeutics worth $2.12K as of Q2 2026.
  • Marquette Asset Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #593 holding.
  • Marquette Asset Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.